证券之星消息，8月13日医疗服务板块较上一交易日上涨4.02%，创新医疗领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流入19.62亿元，游资资金净流出7449.63万元，散户资 金净流出18.88亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | = 11.30 乙 | 11.46% | -1.00 Z | -1.02% | -10.30 Z | -10.45% | | 300759 康龙化成 | | 2.48亿 | 9.09% | 4825.42万 | 1.77% | -2.96 Z | - ...

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, with a total of 21,756 billion yuan traded [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing over 3% [1] AI Industry - AI-related stocks surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [2][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.11 billion yuan, up 38.61% [4][5] - The demand for AI servers is expected to grow significantly, driven by increased capital expenditures from major North American cloud service providers [4][5] Innovative Pharmaceuticals - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up, and other companies like Microchip Biotech and WuXi AppTec also posting significant gains [6][8] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [8] Humanoid Robotics - The humanoid robotics sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices [9][11] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases [9][11] - The industry is expected to benefit from various supportive policies and events, including the upcoming World Humanoid Robot Games and other robotics-related conferences [11]

Group 1: Market Performance - The three major indices showed strong performance, with the Shanghai Composite Index rising by 0.48%, surpassing last year's October high, while the Shenzhen Component Index increased by 1.76% and the ChiNext Index surged by 3.62% [1] - Over 2,600 stocks in the two markets experienced gains, with a total trading volume of approximately 2.15 trillion yuan [1] Group 2: Sector Highlights - The computing power, liquid cooling servers, and CPO concept stocks performed exceptionally well, with New Yisheng (300502.SZ) rising over 15%, and other notable gains from Zhongji Xuchuang (300308.SZ) at 11.66% and Cambridge Technology (603083.SH) at 9.93% [1] - PEEK materials saw collective strength, with companies like Huami New Materials (836247.BJ) and Xinhang New Materials (301076.SZ) experiencing significant increases [2] - The non-ferrous metals sector also performed well, with Electric Alloy (300697.SZ) rising over 9% and other companies like Luoyang Molybdenum (603993.SH) and Zhongfu Industrial (600595.SH) showing strong gains [2] Group 3: Economic Insights - Citic Securities noted that poor economic and employment data in the U.S. strengthened market expectations for a Federal Reserve rate cut in September, contributing to a broad rise in the non-ferrous metals sector [3] - The domestic push for "anti-involution" to optimize production factors is expected to enhance profitability across various sectors, benefiting metal prices [3] - The valuation of industrial metals is currently low, indicating potential for upward correction, with a bullish market for non-ferrous metals starting to emerge [3] Group 4: Policy and Market Sentiment - Dongguan Securities highlighted active market sentiment, suggesting an overweight position in the financial sector due to supportive policies aimed at enhancing the attractiveness of domestic capital markets [4] - The number of new A-share accounts opened in July reached 1.96 million, a significant year-on-year increase of 71%, indicating rising market participation and potential business opportunities for the securities industry [4] - Some sectors, including banks, coal, and logistics, experienced declines, with notable drops in stocks like Lu'an Huaneng (601699.SH) and Jiangsu Bank (600919.SH) [4]

此外，美国劳工统计局周二晚发布的数据显示，7月通胀表现相对平稳，分析人士称9月降息的障碍大大 降低，美联储或在下月重启降息。国信证券表示，投融资整体呈现回暖趋势。国内方面，临床前 CRO、临床CRO、CDMO业务价格止跌回稳，随着新签订单的稳步复苏，行业或将迎来反转；国际 CDMO业务方面，定价体系持续维持合理水平，疫情高基数影响已消化。 CRO概念股涨幅居前，截至发稿，维亚生物(01873)涨12.83%，报2.11港元；昭衍新药（603127） (06127)涨9.23%，报24.62港元；康龙化成（300759）(03759)涨7.27%，报22.12港元；药明康德 （603259）(02359)涨5.49%，报105.6港元；药明生物(02269)涨3.72%，报30.66港元。 消息面上，药明康德此前发布业绩并上调全年销售预期，公司上半年TIDES业务收入达到人民币50.3亿 元，同比增长141.6%，TIDES订单增长或与GLP-1领域需求高涨相关。中金公司（601995）认为，如今 创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药 项目融资活跃度提升，内 ...

昭衍新药（603127）(06127)尾盘涨超9%，截至发稿，涨9.23%，报24.62港元，成交额3.91亿港元。 与市场观点不同，市场顾虑FDA新政影响及海外业务增长潜力，但该行认为：新政以单抗领域为切入点 进行尝试且国内尚未跟进。中短期看，动物实验3-5年内仍为全球药物安评领域的绝对主流方法；长期 看，新方法学(AI、类器官等)应用前景仍待观察，需结合其过渡期内的对比结果及远期技术成熟度综合 考量。该行看好动物实验与新方法学协同演进推动行业整体发展，并看好公司通过新方法学的积极布局 进一步提升综合能力。 华泰证券发布研报称，昭衍新药在历经18-22年的业绩高增，23-25年的订单量价承压调整后，利空逐渐 出清，26年起有望凭借国内复苏(BD出海热潮、IND数量上升)+海外离岸外包双轮驱动进入新一轮增长 通道。报告指出，实验猴价格是安评行业供需关系和周期性的风向标，国内目前位于8-10万元/只，企 稳后略有上升，供需端处于紧平衡状态。该行认为，伴随后续供需缺口拉大，猴价或逐渐进入新一轮上 升周期(22年时高达15-20万元/只)。 ...

Core Viewpoint - Zhaoyan New Drug (06127) has seen a significant stock price increase of over 9%, currently trading at 24.62 HKD, with a transaction volume of 391 million HKD, indicating positive market sentiment towards the company [1] Group 1: Company Performance and Outlook - Huatai Securities reports that Zhaoyan New Drug experienced high growth from 2018 to 2022, but is facing order volume and price pressures from 2023 to 2025. However, starting in 2026, the company is expected to enter a new growth phase driven by domestic recovery and overseas outsourcing [1] - The report highlights that the price of experimental monkeys, a key indicator of supply and demand in the safety evaluation industry, is currently stable at 80,000 to 100,000 RMB per monkey, with a potential upward trend as supply-demand gaps widen [1] Group 2: Market Concerns and Long-term Perspectives - Contrary to market concerns regarding the impact of FDA new policies and overseas business growth potential, Huatai Securities believes that the new policies are primarily focused on monoclonal antibodies and have not yet been adopted domestically. Animal testing will remain the dominant method in global drug safety evaluation for the next 3-5 years [1] - The long-term application of new methodologies such as AI and organoids is still uncertain, requiring careful consideration of transitional results and technological maturity. The company is expected to enhance its overall capabilities through proactive engagement with new methodologies [1]

天眼查商业履历信息显示，北京昭衍新药研究中心股份有限公司，成立于1998年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本53564.4275万人民币，实缴资本4560.33万人民币。公 司法定代表人为冯宇霞。 通过天眼查大数据分析，北京昭衍新药研究中心股份有限公司共对外投资了20家企业，参与招投标项目 44次，知识产权方面有商标信息70条，专利信息54条，此外企业还拥有行政许可44个。 来源：金融界 资金流向方面，今日主力资金净流入2.27亿元，占比成交额12.81%。其中，超大单净流入1.99亿元、占 成交额11.25%，大单净流入2752.09万元、占成交额1.55%，中单净流出流出8315.43万元、占成交额 4.7%，小单净流出14356.95万元、占成交额8.11%。 昭衍新药最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少11.54%，归属净利 润4111.95万元，同比增长115.11%，扣非净利润2566.26万元，同比增长109.14%，流动比率4.613、速动 比率3.221、资产负债率13.96%。 金融界消息 截至2025年8月13日收盘， ...

Group 1 - The core viewpoint of the articles highlights a significant rise in the innovative drug sector, driven by the establishment of a new pricing mechanism for newly launched drugs by the National Medical Insurance Administration [1][2] - The new pricing mechanism is expected to provide higher pricing flexibility, more efficient listing processes, and longer price stability periods for high-quality innovative drugs [1] - Companies in the innovative drug sector, such as Shouyao Holdings and Microchip Biotech, have seen substantial stock price increases, indicating positive market sentiment towards the sector [1] Group 2 - Since 2025, the government has repeatedly proposed policies to optimize drug procurement and support innovative drugs, indicating a favorable policy environment for the development of innovative drugs [2] - The investment strategy for the second half of 2025 suggests a high certainty of performance and valuation recovery in the healthcare industry, driven by external factors such as policy optimization and the rise of commercial health insurance [2] - The trend towards self-sufficiency and the reform of out-of-hospital marketing models are seen as more certain investment directions in the context of true innovation and internationalization in the pharmaceutical sector [2]

Group 1 - The A-share market is experiencing a surge in the pharmaceutical sector, particularly in innovative drugs, with Hai Si Ke reaching its daily limit and Di Zhe Pharmaceutical rising over 8% [1] - The National Healthcare Security Administration has announced the preliminary review of 121 drug names for inclusion in the commercial insurance innovative drug directory, including high-priced CAR-T cancer drugs [1] - The medical sector is seeing a rebound driven by CXO, with the largest medical ETF (512170) hitting a 1.9% increase, and major stocks like Zhaoyan New Drug rising over 8% [3] Group 2 - A new action plan for the high-quality development of "Artificial Intelligence + Healthcare" in Zhejiang Province has been released, focusing on creating multimodal medical industry models and specialized healthcare models [5] - Recent institutional insights suggest that the pharmaceutical sector, led by innovative drugs, is viewed positively for long-term investment, while medical devices are also gaining attention [5] - The largest medical ETF (512170) focuses on medical devices (52%) and medical services (40%), with a strong correlation to AI healthcare, covering six leading CXO stocks [6]

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]